Senate adopts second substitute tightening medical cannabis rules on IDs, delivery and anti‑competitive enforcement

Senators adopted a second substitute to Senate Bill 233 on Feb. 16, 2024 that contains a package of technical and enforcement changes to Utah’s medical cannabis program.

Sponsor Sen. Luz Escamilla said the substitute mirrors existing pharmacy identification requirements to remove ambiguity, narrows the earlier draft’s broad delivery allowance to permit delivery to a patient’s home or workplace (with enumerated exceptions such as schools and churches), and adds coordination among the Division of Consumer Protection, the Attorney General and the Department of Agriculture and Food to investigate anti‑competitive practices in the regulated medical cannabis market.

The substitute also creates a complaint pathway allowing government employees who allege unlawful employment discrimination based on medical cannabis cardholder status to pursue relief through the labor commission. Escamilla emphasized the changes reflect committee input and ongoing stakeholder engagement.

The second substitute passed on a roll call vote and was ordered to third reading. The sponsor characterized the bill as an annual omnibus update for the medical cannabis program that refines enforcement tools and operational rules, while continuing to restrict the program’s scope to medical use.